Page 122 - 南京医科大学学报自然科学版

第43卷第10期
·1448 · 南 京 医 科 大 学 学 报 2023年10月

ficient cancer immunotherapy：advances in developing ar⁃ indirect caccine eradicate a variety of large solid tumors
tificial antigen ⁃ presenting cells［J］. Trends Biotechnol， in an immunocompetent，self ⁃ antigen setting［J］. Clin

2014，32（9）：456-465 Cancer Res，2017，23（10）：2478-2490
［8］ FANG R H，HU C M，LUK B T，et al. Cancer cell mem⁃ ［20］ REINHARD K，RENGSTL B，OEHM P，et al. An RNA
brane⁃coated nanoparticles for anticancer vaccination and vaccine drives expansion and efficacy of claudin⁃CAR⁃T
drug delivery［J］. Nano Lett，2014，14（4）：2181-2188 cells against solid tumors［J］. Science，2020，367（6476）：
［9］ GOTO T，NISHIDA T，TAKAGI E，et al. Programmed 446-453
death⁃ligand 1 on antigen⁃presenting cells facilitates the ［21］ SMITH T T，STEPHAN S B，MOFFETT H F，et al. In situ
induction of antigen⁃specific cytotoxic T lymphocytes：ap⁃ programming of leukaemia⁃specific T cells using synthetic
plication to adoptive T⁃cell immunotherapy［J］. J Immuno⁃ DNA nanocarriers［J］. Nat Nanotechnol，2017，12（8）：
ther，2016，39（8）：306-315 813-820
［10］ PRAKKEN B，WAUBEN M，GENINI D，et al. Artificial ［22］ SOCKOLOSKY J T，TROTTA E，PARISI G，et al. Selec⁃
antigen⁃presenting cells as a tool to exploit the immune tive targeting of engineered T cells using orthogonal IL⁃2
‘synapse’［J］. Nat Med，2000，6（12）：1406-1410 cytokine ⁃ receptor complexes［J］. Science，2018，359
［11］ DAHOTRE S N，ROMANOV A M，SU F Y，et al. Synthetic （6379）：1037-1042
antigen ⁃ presenting cells for adoptive T cell therapy［J］. ［23］ D’ALOIA M M，ZIZZARI I G，SACCHETTI B，et al. CAR⁃
Adv Ther（Weinh），2021，4（8）：2100034 T cells：the long and winding road to solid tumors［J］.
［12］ SUNSHINE J C，PERICA K，SCHNECK J P，et al. Particle Cell Death Dis，2018，9（3）：282
+
shape dependence of CD8 T cell activation by artificial ［24］ PARKHURST M R，RILEY J P，DUDLEY M E，et al.
antigen presenting cells［J］. Biomaterials，2014，35（1）： Adoptive transfer of autologous natural killer cells leads
269-277 to high levels of circulating natural killer cells but does
［13］ MEYER R A，SUNSHINE J C，PERICA K，et al. Biode⁃ not mediate tumor regression［J］. Clin Cancer Res，2011，
gradable nanoellipsoidal artificial antigen presenting 17（19）：6287-6297
cells for antigen specific T ⁃ cell activation［J］. Small， ［25］ HUANG Y，CHEN Y，ZHOU S，et al. Dual⁃mechanism
2015，11（13）：1519-1525 based CTLs infiltration enhancement initiated by nano ⁃
［14］ CHEUNG A S，ZHANG D K Y，KOSHY S T，et al. Scaf⁃ sapper potentiates immunotherapy against immune ⁃ ex⁃
folds that mimic antigen⁃presenting cells enable ex vivo cluded tumors［J］. Nat Commun，2020，11（1）：622
expansion of primary T cells［J］. Nat Biotechnol，2018，36 ［26］ CHEN Q，HU Q，DUKHOVLINOVA E，et al. Photother⁃
（2）：160-169 mal therapy promotes tumor infiltration and antitumor
［15］ CHIANG C S，LIN Y J，LEE R，et al. Combination of fu⁃ activity of CAR T cells［J］. Adv Mater，2019，31（23）：
coidan⁃based magnetic nanoparticles and immunomodula⁃ e1900192
tors enhances tumour ⁃ localized immunotherapy［J］. Nat ［27］ DING N，ZOU Z，SHA H，et al. iRGD synergizes with
Nanotechnol，2018，13（8）：746-754 PD⁃1 knockout immunotherapy by enhancing lymphocyte
［16］ PERICA K，TU A，RICHTER A，et al. Magnetic field⁃in⁃ infiltration in gastric cancer［J］. Nat Commun，2019，10
duced T cell receptor clustering by nanoparticles enhanc⁃ （1）：1336
es T cell activation and stimulates antitumor activity［J］. ［28］ ZHANG F，STEPHAN S B，ENE C I，et al. Nanoparticles
ACS Nano，2014，8（3）：2252-2260 that reshape the tumor milieu create a therapeutic window
［17］ ICHIKAWA J，YOSHIDA T，ISSER A，et al. Rapid ex⁃ for effective T ⁃ cell therapy in solid malignancies［J］.
pansion of highly functional antigen⁃specific T cells from Cancer Res，2018，78（13）：3718-3730
patients with melanoma by nanoscale artificial antigen ⁃ ［29］ ZHENG Y，STEPHAN M T，GAI S A，et al. In vivo target⁃
presenting cells［J］. Clin Cancer Res，2020，26（13）： ing of adoptively transferred T⁃cells with antibody⁃and
3384-3396 cytokine ⁃ conjugated liposomes［J］. J Control Release，
［18］ ZHANG Q，WEI W，WANG P，et al. Biomimetic magneto⁃ 2013，172（2）：426-435
somes as versatile artificial antigen⁃presenting cells to po⁃ ［30］ ZHENG Y ，TANG L ，MABARDI L ，et al. Enhancing
tentiate T⁃cell⁃based anticancer therapy［J］. ACS Nano， adoptive cell therapy of cancer through targeted delivery
2017，11（11）：10724-10732 of small ⁃ molecule immunomodulators to internalizing or
［19］ SLANEY C Y，VON SCHEIDT B，DAVENPORT A J，et noninternalizing receptors［J］. ACS Nano，2017，11（3）：
al. Dual⁃specific chimeric antigen receptor T cells and an 3089-3100